ArticleHeliyon2024
High sensitive aptasensing chronic myeloid leukemia on circular electrode-modified by single-walled carbon nanotube.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibody-aptamer Complementation: Advancing Biosensing for Disease Monitoring.Current topics in medicinal chemistry · 2026Review
- Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy.Clinical and experimental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic myeloid leukemia (CML) is a cancer in the bone marrow caused by the proliferation of granulocyte cells at all the maturation stages. Late diagnosis of CML decreases the patient survival rate, makes diagnosing CML is mandatory before entering the blastic phase. CD 19 is an important target for CML and is effectively utilized for therapeutic and diagnosis purposes. This research was focused on developing an aptamer-mediated circular interdigitated electrode (IDE) sensor for detecting the level of CD 19 and measured at 0-2 V with the step of 0.1 V. To improve the surface functionalization on IDE, the surface of IDE was modified with a single-walled carbon nanotube (SWCN) to enhance the aptamer immobilization. SWCN increased the aptamer attachment and also enhanced the analytical performances on IDE. This SWCN-aptamer modified IDE detected the CD 19 as low as 10 nM on a linear co-regression range from 10 to 100 nM [y = 2.0126x - 2.3857; R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.